Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Liabilities and Shareholders Equity: 2019-2025

Historic Liabilities and Shareholders Equity for Legend Biotech (LEGN) over the last 5 years, with Sep 2025 value amounting to $1.7 billion.

  • Legend Biotech's Liabilities and Shareholders Equity fell 1.32% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 billion, marking a year-over-year decrease of 6.55%. This contributed to the annual value of $1.7 billion for FY2024, which is 9.65% down from last year.
  • Latest data reveals that Legend Biotech reported Liabilities and Shareholders Equity of $1.7 billion as of Q3 2025, which was up 1.36% from $1.7 billion recorded in Q2 2025.
  • Over the past 5 years, Legend Biotech's Liabilities and Shareholders Equity peaked at $1.9 billion during Q2 2023, and registered a low of $615,253 during Q1 2021.
  • Over the past 3 years, Legend Biotech's median Liabilities and Shareholders Equity value was $1.7 billion (recorded in 2024), while the average stood at $1.7 billion.
  • In the last 5 years, Legend Biotech's Liabilities and Shareholders Equity skyrocketed by 169,614.57% in 2022 and then dropped by 9.65% in 2024.
  • Over the past 5 years, Legend Biotech's Liabilities and Shareholders Equity (Quarterly) stood at $1.1 billion in 2021, then rose by 18.89% to $1.3 billion in 2022, then surged by 38.89% to $1.8 billion in 2023, then fell by 9.65% to $1.7 billion in 2024, then dropped by 1.32% to $1.7 billion in 2025.
  • Its Liabilities and Shareholders Equity stands at $1.7 billion for Q3 2025, versus $1.7 billion for Q2 2025 and $1.6 billion for Q1 2025.